Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
paper
Cited
Public
- Authors
- Kranzler, Henry R; Soyka, Michael
- Year
- 2018
- Journal
- JAMA
- PMID
- 30167705
- DOI
- 10.1001/jama.2018.11406
- PMCID
- PMC7391072
IMPORTANCE: Alcohol consumption is associated with 88β―000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility. OBSERVATIONS: Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments. CONCLUSIONS AND RELEVANCE: Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.
No figures extracted from this document.
| # | Section | Preview |
|---|---|---|
| 40 | OBSERVATIONS β Treatment: β Non-FDA-Approved Medications for Treating Alcohol Use Disorder (Table 2) β Combining Psychosocial Treatments with Alcohol Treatment Medications. | specialists. Group assignments were randomized for both the medication (which was administeredβ¦ |
| 41 | OBSERVATIONS β Treatment: β Non-FDA-Approved Medications for Treating Alcohol Use Disorder (Table 2) β Recommended Approach to Treatment: | Patients diagnosed with an AUD should be advised to substantially reduce or stop their alcohol use.β¦ |
| 42 | OBSERVATIONS β Treatment: β Non-FDA-Approved Medications for Treating Alcohol Use Disorder (Table 2) β Recommended Approach to Treatment: | Patients whose drinking does not respond to this approach or who seek or would benefit from moreβ¦ |
| 43 | OBSERVATIONS β Treatment: β Non-FDA-Approved Medications for Treating Alcohol Use Disorder (Table 2) β Prognosis: | Because AUD has a chronic, relapsing course, ongoing clinical management is required. In the absenceβ¦ |
| 44 | LIMITATIONS | This review has some limitations. First, the literature on medications to treat AUD is limited.β¦ |
| 45 | CONCLUSIONS | Validated screening methods are available to identify patients with heavy alcohol use. Patients who⦠|
β Prev
41β46 of 46
| Name | Type |
|---|---|
| 1,383 patients local | cohort |
| 18β25 years local | cohort |
| 21β25 years local | cohort |
| 30-day abstinence local | phenotype |
| abdominal pain local | phenotype |
| Abnormal muscle movements local | phenotype |
| abstinence | phenotype |
| Abstinent days local | phenotype |
| acamprosate | drug |
| acetaldehyde | drug |
| aggression | phenotype |
| alcohol | phenotype |
| alcohol dependence | phenotype |
| Alcohol Dependence Symptoms | phenotype |
| alcoholism | phenotype |
| alcohol-related problems | phenotype |
| Alcohol Use Disorder | phenotype |
| ALDH2 | gene |
| anorexia nervosa | phenotype |
| antisocial personality disorder | phenotype |
| Asian | cohort |
| ataxia | phenotype |
| AUD | phenotype |
| AUD Cross-Sectional Survey Cohort local | cohort |
| AUDIT | phenotype |
| AUDIT-C | phenotype |
| baclofen | drug |
| Baclofen >60 mg/day local | drug |
| Baclofen β€60 mg/day local | drug |
| binge drinking | phenotype |
| Binge_drinking_days local | phenotype |
| bipolar I disorder | phenotype |
| blacks | cohort |
| Blinded trials local | cohort |
| borderline personality disorder | phenotype |
| cancer | phenotype |
| cannabinoids | drug |
| Cardiovascular collapse local | phenotype |
| cardiovascular disease | phenotype |
| Childhood and adolescent stressors local | phenotype |
| Colon cancer | phenotype |
| Combined behavioral intervention | drug |
| Combine Study | cohort |
| comparison group | cohort |
| confusion | phenotype |
| confusional states local | phenotype |
| Daily alcohol use local | phenotype |
| decreased appetite | phenotype |
| delta opioid receptor | drug |
| Delta-opioid receptor local | drug |
| Department of Veterans Affairs/Department of Defense local | cohort |
| Depressed AUD cohort local | cohort |
| depression | phenotype |
| diabetes | phenotype |
| Diarrhea | phenotype |
| Difficulty with concentration/attention local | phenotype |
| disulfiram | drug |
| Disulfiram-ethanol reaction local | phenotype |
| dizziness | phenotype |
| dopamine | drug |
| drinking | phenotype |
| drowsiness | phenotype |
| drug dependence | phenotype |
| Dysgeusia local | phenotype |
| Enacarbil ER local | drug |
| endogenous opioids | drug |
| epilepsy | phenotype |
| European multi-center trials local | cohort |
| Excessive perspiration local | phenotype |
| fatigue | phenotype |
| FDA-approved AUD medication local | drug |
| FDAβapproved AUD medications local | drug |
| flushing | phenotype |
| frequency of alcohol use | phenotype |
| GABA | phenotype |
| gabapentin | drug |
| gabapentin misuse local | phenotype |
| gait disorder local | phenotype |
| Gastrointestinal Disease local | phenotype |
| general population | cohort |
| genetic variants | cohort |
| glutamate | drug |
| hazardous drinking | phenotype |
| headache | phenotype |
| Head Cancer local | phenotype |
| Health maintenance organization cohort local | cohort |
| heavy drinking | phenotype |
| hepatitis | phenotype |
| High-dose baclofen patients local | cohort |
| Higher daily alcohol use at baseline local | phenotype |
| Higher success rate local | phenotype |
| Hispanic | phenotype |
| Household instability local | phenotype |
| humans | cohort |
| hypotension | phenotype |
| hypothalamic-pituitary-adrenal axis | anatomy |
| injection site reactions local | phenotype |
| insomnia | phenotype |
| Intramuscular_naltrexone_380mg local | variant |
| Itching/pruritis local | phenotype |
| kappa opioid receptor | drug |
| Kappa-opioid receptor local | drug |
| liver cancer | phenotype |
| liver disease | phenotype |
| Low-dose baclofen study local | cohort |
| Lowβintensity behavioral treatment local | drug |
| major depressive disorder | phenotype |
| male veterans local | cohort |
| Married or cohabiting local | cohort |
| medical management | drug |
| medication | drug |
| medications for AUD local | drug |
| Mental slowing local | phenotype |
| mesolimbic dopamine system | drug |
| Meta-analysis of 5 RCTs local | cohort |
| migraine | phenotype |
| mu opioid receptor | drug |
| Muscle stiffness local | phenotype |
| nalmefene | drug |
| naltrexone | drug |
| Naltrexone_190mg_month local | variant |
| Naltrexone_380mg_month local | variant |
| Native Americans | cohort |
| nausea | phenotype |
| Neck Cancer local | phenotype |
| nervousness | phenotype |
| neuropathic pain | phenotype |
| neuropathy local | phenotype |
| Never married local | cohort |
| No binge drinking local | phenotype |
| non-Hispanic whites | cohort |
| Non-supervised treatment local | cohort |
| norepinephrine | drug |
| Numbness local | phenotype |
| Off-label medication local | drug |
| Open-label studies local | cohort |
| opioid | drug |
| opioid withdrawal | phenotype |
| optic neuritis local | phenotype |
| Oral_naltrexone_50mg local | variant |
| orbitofrontal cortex | anatomy |
| Pacific Islanders local | cohort |
| Palpitations | phenotype |
| pancreatitis | phenotype |
| parental alcoholism | phenotype |
| Paresthesia local | phenotype |
| past-year drinking | phenotype |
| Percentage of abstinent days local | phenotype |
| Percentage of days abstinent local | phenotype |
| peripheral edema local | phenotype |
| pharmacological treatment | drug |
| pharmacotherapy | drug |
| Phentermine local | drug |
| physical abuse | phenotype |
| Placebo patients local | cohort |
| prefrontal cortex | anatomy |
| primary care | cohort |
| Pruritis local | phenotype |
| psychosis | phenotype |
| psychosocial problems | phenotype |
| Psychosocial therapy local | drug |
| RCT_624 local | cohort |
| RCTs | cohort |
| Rectal Cancer local | phenotype |
| Reduced verbal fluency local | phenotype |
| Reduced working memory local | phenotype |
| Relapse to any drinking local | phenotype |
| sedatives | drug |
| Separated/divorced/widowed local | cohort |
| serotonin | drug |
| sertraline | drug |
| Sertraline + Naltrexone local | drug |
| severe alcohol use disorder | phenotype |
| sex | phenotype |
| single-item questionnaire local | phenotype |
| slurred speech | phenotype |
| somnolence | phenotype |
| spasticity | phenotype |
| specific phobia | phenotype |
| substance use | phenotype |
| suicide | phenotype |
| Supervised ingestion local | cohort |
| sweating | phenotype |
| Time to first lapse to drinking local | phenotype |
| topiramate | drug |
| trauma | phenotype |
| treatment samples | cohort |
| unhealthy alcohol use | phenotype |
| United States | cohort |
| Verbal abuse | phenotype |
| Veteran_pilot_study local | cohort |
| Veterans Affairs Health System local | cohort |
| Veterans Health Administration | cohort |
| violence | phenotype |
| voluntary alcohol consumption | phenotype |
| vomiting | phenotype |
| weight loss | phenotype |
| withdrawal | phenotype |
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AmbrogneJA. Reduced-risk drinking as a treatment goal: what clinicians need to know. J Subst Abuse Treat. 2002;22(1(:45β53.1184990610.1016/s0740-5472(01)00210-0 | β | β | β |
| American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing, 2013. | β | β | β |
| AntonRF, OβMalleySS, CirauloDA, Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006;295(17):2003β2017.1667040910.1001/jama.295.17.2003 | β | β | β |
| BlodgettJC, Del ReAC, MaiselNC, FinneyJW. A meta-analysis of topiramateβs effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481β1488.2479649210.1111/acer.12411PMC4047180 | β | β | β |
| BohnMJ, BaborTF, KranzlerHR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423β32.767467810.15288/jsa.1995.56.423 | β | β | β |
| BrownSA, InabaRK, GillinJC, SchuckitMA, StewartMA, IrwinMR. Alcoholism and affective disorder: clinical course of depressive symptoms. Am J Psychiatry. 1995;152(1):45β52.780211910.1176/ajp.152.1.45 | β | β | β |
| BuschAC, ShivaramM, GlassJE, Pre-discharge injectable vs. oral naltrexone to improve post-discharge treatment engagement among hospitalized veterans with alcohol use disorder: A randomized pilot proof-of-concept study. Alcohol Clin Exp Res. 2017;41(7):1352β1360.2860582710.1111/acer.13410PMC5519139 | β | β | β |
| BushK, KivlahanDR, McDonellMB, FihnSD, BradleyKA. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789β1795.973860810.1001/archinte.158.16.1789 | β | β | β |
| Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Detailed Tables Substance Abuse and Mental Health Services Administration, Rockville, MD, 2017 Retrieved from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf. Accessed June 16, 2018. | β | β | β |
| Centers for Disease Control and Prevention (CDC). 2013 Alcohol and public health: Alcohol-related disease impact (ARDI). Average for United States 2006β2010 alcohol-attributable deaths due to excessive alcohol use. Available at: https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&P=f6d7eda7-036e-4553-9968-9b17ffad620e&R=d7a9b303-48e9-4440-bf47-070a4827e1fd&M=8E1C5233-5640-4EE8-9247-1ECA7DA325B9&F=&D. Accessed April 19, 2018. | β | β | β |
| Centers for Disease Control and Prevention. Excessive drinking is draining the U.S. economy. Centers for Disease Control and Prevention; 2016 Available at: https://www.cdc.gov/features/costsofdrinking/index.html. Accessed April 19, 2018. | β | β | β |
| ChickJ Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20(5):427β35.1034809310.2165/00002018-199920050-00003 | β | β | β |
| Del ReAC, GordonAJ, LembkeA, HarrisAH. Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract. 2013;8:12.2383535210.1186/1940-0640-8-12PMC3716908 | β | β | β |
| Department of Veterans Affairs/Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGFinal1.pdf Accessed April 21, 2018. | β | β | β |
| DonoghueK, ElzerbiC, SaundersR, WhittingtonC, PillingS, DrummondC. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction 2015;110(6):920β930.2566449410.1111/add.12875 | β | β | β |
| DubeSR, AndaRF, FelittiVJ, EdwardsVJ, CroftJB. Adverse childhood experiences and personal alcohol abuse as an adult. Addict Behav. 2002;27(5):713β725.1220137910.1016/s0306-4603(01)00204-0 | β | β | β |
| FalkD, WangXQ, LiuL, Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res. 2010;34(12):2022β34.2065906610.1111/j.1530-0277.2010.01290.x | β | β | β |
| FalkDE, RyanML, FertigJB, LittenRZ. Gabapentin enacarbil extendedβrelease for the treatment of alcohol use disorder: A multiβsite, randomized, double blind, placeboβcontrolled trial. Alcohol Clin Exp Res. 2018;42(S1):67A.10.1111/acer.13917PMC631799630403402 | β | β | β |
| FullerRK, BrancheyL, BrightwellDR Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256(11):1449β1455.3528541 | β | β | β |
| GarbuttJC, KranzlerHR, OβMalleySS Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293(13):1617β1625.1581198110.1001/jama.293.13.1617 | β | β | β |
| GrantBF, GoldsteinRB, SahaTD, Epidemiology of DSM-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757β66. REPLACE WITH GRANT ET AL. 2017?2603907010.1001/jamapsychiatry.2015.0584PMC5240584 | β | β | β |
| GuerzoniS, PellesiL, PiniLA, CaputoF. Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacol Res. 2018;133:65β76.2971920410.1016/j.phrs.2018.04.024 | β | β | β |
| HarrisAH, OlivaE, BoweT, HumphreysKN, KivlahanDR, TraftonJA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679β85.2254927610.1176/appi.ps.201000553 | β | β | β |
| HauserP, FullerB, HoSB, ThurasP, KernS, DieperinkE. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017;112(7):1173β1183.2819262210.1111/add.13787 | β | β | β |
| HillemacherT, LeggioL, HeberleinA. Investigational therapies for the pharmacological treatment of alcoholism. Exert Opin Invesig Drugs. 2015(1);24:17β30.10.1517/13543784.2014.954037PMC1243441525164385 | β | β | β |
| JohnsonBA, RosenthalN, CapeceJA, Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641β51.1792551610.1001/jama.298.14.1641 | β | β | β |
| JonasDE, AmickHR, FeltnerC; Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA. 2014;311(18):1889β1900.2482564410.1001/jama.2014.3628 | β | β | β |
| JonesJD, ComerSD, KranzlerHR. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res. 2015;39(3):391β402.2570350510.1111/acer.12643PMC4348335 | β | β | β |
| KanerEF, BeyerFR, MuirheadC, CampbellF, PienaarED, BertholetN, DaeppenJB, SaundersJB, BurnandB. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2:CD004148.2947665310.1002/14651858.CD004148.pub4PMC6491186 | β | β | β |
| KnappCM, CirauloDA, Sarid-SegalO, Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34β42.2542717110.1097/JCP.0000000000000246PMC4276485 | β | β | β |
| KranzlerHR, ArmeliS, TennenH, BlomqvistO, OnckenC, PetryN, FeinnR. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23(3):294β304.1282699110.1097/01.jcp.0000084030.22282.6d | β | β | β |
| KranzlerHR, CovaultJ, FeinnR, Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445β452.2452569010.1176/appi.ajp.2013.13081014PMC3997125 | β | β | β |
| KranzlerHR, KnappC, CirauloD. Pharmacotherapy of alcoholism In KranzlerHR, CirauloD, ZindelL (Eds), Clinical Manual of Addiction Psychopharmacology, 2nd ed., Washington, DC: American Psychiatric Press, Inc., 2014. | β | β | β |
| KristonL, HolzelL, WeiserA-K, BernerMM, HarterM. Meta-analysis: are 3 questions enough to detect unhealthy alcohol use? Ann Intern Med. 2008;149(12):879β888.1907520710.7326/0003-4819-149-12-200812160-00007 | β | β | β |
| LeungJG, Hall-FlavinD, NelsonS, SchmidtKA, SchakKM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015;49(8):897β906.2596957010.1177/1060028015585849 | β | β | β |
| MaiselNC, BlodgettJC, WilbournePL, HumphreysK, FinneyJW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275β93.2307528810.1111/j.1360-0443.2012.04054.xPMC3970823 | β | β | β |
| MarkTL, KassedCA, Vandivort-WarrenR, LevitKR, KranzlerHR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1β3):345β349.1881975910.1016/j.drugalcdep.2008.07.018PMC3166770 | β | β | β |
| MasonBJ, QuelloS, GoodellV, Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174 :70β77.2419057810.1001/jamainternmed.2013.11950PMC3920987 | β | β | β |
| McKnight-EilyLR, LiuY, BrewerRD, Vital signs: Communication between health professionals and their patients about alcohol use - 44 states and the District of Columbia, 2011. MMWR. 2014;63(1):16β22.24402468PMC5779334 | β | β | β |
| Moyer VAUS Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013;159(3):210β2182369879110.7326/0003-4819-159-3-201308060-00652 | β | β | β |
| NaudetF, FitzgeraldN, BraillonA. Nalmefene for alcohol dependence: a NICE decision? Lancet Psychiatry. 2016;3(12):1104β1105.2788900710.1016/S2215-0366(16)30356-X | β | β | β |
| NoronhaABC, CuiC, HarrisRA, CrabbeJC, eds. Neurobiology of Alcohol Dependence. London, Waltham, San Diego: Academic Press; 2014. | β | β | β |
| OdlaugBL, GualA, DeCourcyJ, Alcohol dependence, co-occurring conditions and attributable burden. Alcohol Alcohol 2016(2); 51:201β209.2624651410.1093/alcalc/agv088PMC4755551 | β | β | β |
| OβMalleySS, GarbuttJC, GastfriendDR, DongQ, KranzlerHR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007;27(5):507β12.1787368610.1097/jcp.0b013e31814ce50d | β | β | β |
| OβMalleySS, JaffeAJ, ChangG, SchottenfeldRS, MeyerRE, RounsavilleB. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881β7.144472610.1001/archpsyc.1992.01820110045007 | β | β | β |
| PalpacuerC, DuprezR, HuneauA, Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220β237.2894086610.1111/add.13974 | β | β | β |
| PalpacuerC, LaviolleB, BoussageonR, ReymannJM, BellissantE, NaudetF. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: A systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.2669452910.1371/journal.pmed.1001924PMC4687857 | β | β | β |
| PetryNM, LedgerwoodDM, McKayJR. Treatment of substance use disorders In KranzlerHR, CirauloDA, ZindelLR (Eds), Clinical Manual of Addiction Psychopharmacology, 2nd Edition Washington, DC: American Psychiatric Publishing; 2014: pp. 387β412. | β | β | β |
| PettinatiHM, OslinDW, KampmanKM, DundonWD, XieH, GallisTL, DackisCA, OβBrienCP. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668β75.2023132410.1176/appi.ajp.2009.08060852PMC3121313 | β | β | β |
| PierceM, SutterlandA, BerahaEM, MorleyK, van den BrinkW. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. Eur Neuropsychopharm 2018 6 19 pii: S0924β977X(18)30093β2. doi: 10.1016/j.euroneuro.2018.03.017. [Epub ahead of print]29934090 | β | β | β |
| RehmJ, DawsonD, FrickU, Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2014;38(4):1068β107.2442819610.1111/acer.12331PMC4147870 | β | β | β |
| ReusVI, FochtmanLJ, BuksteinO, The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. Am J Psychiatry 2018;175: 86β90.2930142010.1176/appi.ajp.2017.1750101 | β | β | β |
| ReynaudM, AubinHJ, TrinquetF, A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR Study. Alcohol Alcohol. 2017;52(4):439β446.2852555510.1093/alcalc/agx030 | β | β | β |
| RΓΆsnerS, Hackl-HerrwerthA, LeuchtS, LehertP, VecchiS, SoykaM. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010: CD004332.2082483710.1002/14651858.CD004332.pub2PMC12147086 | β | β | β |
| RΓΆsnerS, Hackl-HerrwerthA, LeuchtS, VecchiS, SrisurapanontM, SoykaM. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010:CD001867.2115434910.1002/14651858.CD001867.pub3 | β | β | β |
| SkinnerMD, LahmekP, PhamH, AubinHJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.2452033010.1371/journal.pone.0087366PMC3919718 | β | β | β |
| SmithRV, HavensJR, WalshSL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160β74.2726542110.1111/add.13324PMC5573873 | β | β | β |
| Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health (NSDUH) 2015 (NSDUH-2015-DS0001). Public-Use File Dataset. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-ServiceUseAdult-2015/NSDUH-ServiceUseAdult-2015/NSDUH-ServiceUseAdult-2015.htm. Accessed June 5, 2018. | β | β | β |
| U.S. Department of Health and Human Services and U.S. Department of Agriculture 2015β2020 Dietary Guidelines for Americans. 8th Edition 12 2015 Available at http://health.gov/dietaryguidelines/2015/guidelines/. Accessed June 30, 2018. | β | β | β |
| U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Alcoholism: Developing Drugs for Treatment Guidance for Industry. Washington, DC, 201549. | β | β | β |
| van den BrinkW, StrangJ, GualA, SΓΈrensenP, JensenTJ, MannK. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opin Drug Saf. 2015;14(4):495β504.2565276810.1517/14740338.2015.1011619 | β | β | β |
| VerhulstMC, NealeMC, KendlerKS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med. 2015;45(5):1061β10722517159610.1017/S0033291714002165PMC4345133 | β | β | β |
| VolpicelliJR, AltermanAI, HayashidaM, OβBrienCP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876β80.134513310.1001/archpsyc.1992.01820110040006 | β | β | β |
| WeisnerC, MatzgerH, KaskutasLA. How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction 2003;98(7):901β911.1281449610.1046/j.1360-0443.2003.00438.x | β | β | β |
| WiffenPJ, DerryS, BellRF, RiceASC, TΓΆlleTR, PhillipsT, Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017: CD007938.2859747110.1002/14651858.CD007938.pub4PMC6452908 | β | β | β |
| WoodAM, KaptogeS, ButterworthAS, Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513β1523.2967628110.1016/S0140-6736(18)30134-XPMC5899998 | β | β | β |
| World Health Organization. Global status report on alcohol and health 2014 Geneva: World Health Organization. | β | β | β |
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Altered functional diversity in alcohol use disorder: an edge-centric marker linked to neurochemical and transcriptional signatures. | Wang M et al. | β | 2026 | β |
| Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. | Wilkinson CS et al. | β | 2026 | β |
| Early liver transplantation in alcohol-associated liver disease-Evolution of practice, patient selection, management, and outcomes. | Cotter TG et al. | β | 2026 | β |
| FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens. | Cooley BJ et al. | β | 2026 | β |
| Initiation of pharmacotherapy for alcohol use disorder in Japan: a longitudinal descriptive study. | Kitamura M et al. | β | 2026 | β |
| Macrophage pyroptosis inhibition alleviates postinjury neointimal formation and vascular restenosis. | Ji Z et al. | β | 2026 | β |
| Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements. | Feltus SR et al. | β | 2026 | β |
| Medical Treatments and Outcomes in Acute Alcohol-Related Hepatitis. | Lee HD et al. | β | 2026 | β |
| Pharmacotherapy for psychiatric inpatients with alcohol use disorder or acute intoxication: results from an observational pharmacovigilance program-status and changes between 2000 and 2016. | Haack B et al. | β | 2026 | β |
| Population-Level Evidence That Alcohol Brief Interventions Improve Drinking and Blood Pressure Outcomes in Patients With Hypertension and Unhealthy Alcohol Use. | Sterling SA et al. | β | 2026 | β |
| Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use. | Yue Y et al. | β | 2026 | β |
| Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis. | Nasrollahizadeh A et al. | β | 2026 | β |
| Shared neural network dysfunctions in treatment-resistant major depression and alcohol use disorder: Resting-state fMRI evidence and implications for neuromodulation. | Tien Y et al. | β | 2026 | β |
| Socio-economic differences in the effectiveness of pharmacotherapy use in alcohol use disorder: A cohort study of 148β626 individuals in Sweden. | Elling DL et al. | β | 2026 | β |
| Thalamostriatal circuit as a therapeutic target of alcohol use disorder. | Song H et al. | β | 2026 | β |
| The caspase 11/gasdermin D pathway is a key driver of stress-induced neuroinflammation and behavioral dysfunction in rats. | Tiwari S et al. | β | 2026 | β |
| Treatment approaches for alcohol use disorder with metabolic dysfunction. | Wagner AC et al. | β | 2026 | β |
| Treatment of alcohol use disorder via magnetic resonance-guided focused ultrasound ablation surgery. | Wang F et al. | β | 2026 | β |
| A Brief Intervention on Alcohol Use Disorder Is Associated With Treatment Access for Inpatients With Alcohol-associated Liver Disease. | Twohig PA et al. | β | 2025 | β |
| Activation of anoctamin-1 calcium-activated chloride channels reduces voluntary alcohol consumption in rats. | Silva-Cardoso GK et al. | β | 2025 | β |
| Alcohol Use Disorder and HIV Risk in a National Survey of Men Who Have Sex with Men in Ukraine. | Gabriel W et al. | β | 2025 | β |
| Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. | Stewart MT et al. | β | 2025 | β |
| Alcohol use-related problems in general hospitals and primary care settings: Screening, intervention, and referral to treatment. | Lv XF et al. | β | 2025 | β |
| Alcohol Withdrawal Alters the Inhibitory Landscape of the Prelimbic Cortex in an Interneuron- and Sex-specific Manner. | Quadir SG et al. | β | 2025 | β |
| Applying a Modified Version of the Prediction of Alcohol Withdrawal Severity Scale in a Canadian Community Withdrawal Management Setting. | Crepeault H et al. | β | 2025 | β |
| A randomized, double-blind, placebo-controlled trial of N-acetylcysteine as an adjuvant treatment for alcohol use disorder. | Schuch JB et al. | β | 2025 | β |
| Assessing Cravings Among Individuals with Alcohol Dependence Syndrome Prescribed with Anti-craving Medication: A Prospective Observational Study. | Sultana M et al. | β | 2025 | β |
| A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder. | Friske MM et al. | β | 2025 | β |
| Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption. | Jensen ME et al. | β | 2025 | β |
| Cell-free DNA in sepsis: from molecular insights to clinical management. | Li L et al. | β | 2025 | β |
| Co-created improvement goals and strategies for implementing SBIRT and MAUDΒ in primary care settings in a facilitator-supported, tailored implementation study. | Kenzie ES et al. | β | 2025 | β |
| Computer-based training for cognitive behavioral therapy (CBT4CBT): A mixed methods investigation. | Downie D et al. | β | 2025 | β |
| Coping-strategies as a mediator between emotional disorders and problematic alcohol use. | AntuΓ±a-Camblor C et al. | β | 2025 | β |
| Decoding the bidirectional links between alcohol misuse and aggression: toward a unified translational framework. | Russell NM et al. | β | 2025 | β |
| Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo-controlled crossover laboratory study. | Petrakis IL et al. | β | 2025 | β |
| Disulfiram-Ethanol reaction mimicking posterior circulation stroke: A case report. | Trebbastoni A et al. | β | 2025 | β |
| Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial). | Klausen MK et al. | β | 2025 | β |
| Effect of varenicline on major adverse liver outcomes in alcohol-associated liver disease: An exploratory analysis. | Danpanichkul P et al. | β | 2025 | β |
| Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder. | Klausen MK et al. | β | 2025 | β |
| Emergency Medicine Resident Experiences and Perceptions Regarding Medications for the Treatment of Alcohol Use Disorder. | Bia JR et al. | β | 2025 | β |
| Evaluating Resident Physicians' Perceptions of and Improving Utilization of Alcohol Use Disorder Pharmacotherapy: A Quality Improvement Initiative. | Abboud A et al. | β | 2025 | β |
| Experiences and barriers to alcohol use disorder treatment among adults with and without self-reported executive functioning challenges: A mixed-methods study. | Russell C et al. | β | 2025 | β |
| Fatal Disulfiram-Ethanol Reaction in a Patient With Preexisting Cardiac Comorbidities: A Case Report. | G T et al. | β | 2025 | β |
| Galanin(1-15) and Naltrexone: A novel approach for alcohol use disorder in rats, involving the mesolimbic system. | Flores-GΓ³mez M et al. | β | 2025 | β |
| Gender differences in the relationship between alcohol use patterns and health-related quality of life in a population experiencing a recent surge in harmful alcohol use among females: the 2018 National survey in Taiwan. | Chen TY et al. | β | 2025 | β |
| Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment? | Chrysavgis L et al. | β | 2025 | β |
| Goal alignment and unintended consequences of accountable care: How the structure of Oregon's Medicaid coordinated care model shapes health plan-clinic partnerships. | Kenzie ES et al. | β | 2025 | β |
| Identification and Treatment of Alcohol Use Disorder. | Haber PS | β | 2025 | β |
| Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes. | Rashid Z et al. | β | 2025 | β |
| Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder. | Kuo CC et al. | β | 2025 | β |
| Knowledge, attitude, and practice toward atrial fibrillation among patients. | Ye J et al. | β | 2025 | β |
| Machine learning for novel phenotyping in schizophrenia. | Bareis N et al. | β | 2025 | β |
| Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. | DΓaz LA et al. | β | 2025 | β |
| Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes? | Elmustafa F et al. | β | 2025 | β |
| Microbiome-derived metabolites in substance use disorders: Mechanisms and implications. | Koperska M et al. | β | 2025 | β |
| Modern pharmacotherapy guidance for treating alcohol use disorders. | Soyka M et al. | β | 2025 | β |
| Modulation of Alcohol Use Disorder by Brain Stimulation. | Ygael N et al. | β | 2025 | β |
| Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone. | Logge WB et al. | β | 2025 | β |
| Novel educational video module about alcohol use disorder increases treatment rates and decreases return to alcohol use. | Twohig P et al. | β | 2025 | β |
| Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis. | Prasad M et al. | β | 2025 | β |
| Preoperative Alcohol Use Disorder Is Associated With Increased Morbidity and Costs in Ankle Arthrodesis. | McDonald WE et al. | β | 2025 | β |
| Psychological mechanisms of change in reducing co-occurring social anxiety and alcohol use: A causal mediation analysis of the online Inroads intervention. | GΓΌckel T et al. | β | 2025 | β |
| Psychosocial therapy improves outcomes for alcohol use disorder in people with chronic liver disease: A systematic review and meta-analysis. | Sollenberger CH et al. | β | 2025 | β |
| Reduced Mastication Is Associated With Dynapenia Markers in Patients With Cirrhosis: A Cross-Sectional Study. | Brunetto B et al. | β | 2025 | β |
| Relationship between Medicaid coverage design and receipt of medication for alcohol use disorder (MAUD): Probability of receipt increases based on comprehensiveness of plan. | Estrada MAG et al. | β | 2025 | β |
| Sex and Genetic Differences in Behavioral Engagement of Crossed High Alcohol-Preferring and Low Alcohol-Preferring Mice. | Starski P et al. | β | 2025 | β |
| Social network alcohol use is associated with individual-level alcohol use among Black sexually minoritized men and gender-expansive people: Findings from the Neighborhoods and Networks (N2) cohort study. | Shrader CH et al. | β | 2025 | β |
| Social validity of digital social incentives in the treatment of substance use disorders. | Ives LA et al. | β | 2025 | β |
| Statistical methods for assessing treatment effects on ordinal outcomes using observational data. | Hu H et al. | β | 2025 | β |
| Successful Integration of Alcohol Use Disorder Treatment into a Primary Care Clinic at a Safety-Net Hospital. | Lom J et al. | β | 2025 | β |
| [The physical and mental health of home care recipients: A quantitative secondary data analysis]. | Karabegovic A et al. | β | 2025 | β |
| Trends and cross-country inequalities of alcohol use disorders: findings from the global burden of disease study 2021. | Xie Z et al. | β | 2025 | β |
| Type 2 Diabetes Health Care Outcomes for Patients with Alcohol Use Disorder Starting Addiction Treatment. | Iturralde E et al. | β | 2025 | β |
| Variations in documentation of alcohol use disorder (AUD) diagnoses across race, ethnicity, and sex in a health system that assesses AUD symptoms as part of routine primary care. | Ellis RL et al. | β | 2025 | β |
| Alcohol Consumption Patterns for Excessive Drinkers in a Multi-Ethnic Society Short Running Title: Drinking Patterns and Health Education. | Wu Z et al. | β | 2024 | β |
| Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment. | Roldan GA et al. | β | 2024 | β |
| Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin. | Singal AK et al. | β | 2024 | β |
| Alcohol use disorder in the perioperative period: a summary and recommendations for anesthesiologists and pain physicians. | Lane O et al. | β | 2024 | β |
| A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. | Celik M et al. | β | 2024 | β |
| ANK3 rs10994336 and ZNF804A rs7597593 polymorphisms: genetic interaction for emotional and behavioral symptoms of alcohol withdrawal syndrome. | Shen G et al. | β | 2024 | β |
| A reverse translational study of PPAR-Ξ± agonist efficacy in human and rodent models relevant to alcohol use disorder. | Mason BJ et al. | β | 2024 | β |
| Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. | Wang W et al. | β | 2024 | β |
| A Survey of Medication Diffusion and Attitudes Among Indian Clinicians Toward Pharmacotherapies for Alcohol Use Disorder. | Ghosh S et al. | β | 2024 | β |
| Biased allosteric modulator of neurotensin receptor 1 reduces ethanol drinking and responses to ethanol administration in rodents. | Gereau GB et al. | β | 2024 | β |
| Changing landscape of alcohol-associated liver disease in younger individuals, women, and ethnic minorities. | Arab JP et al. | β | 2024 | β |
| Cholinergic Interneurons in the Accumbal Shell Region Regulate Binge Alcohol Self-Administration in Mice: An In Vivo Calcium Imaging Study. | Sharma R et al. | β | 2024 | β |
| Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder. | Zuluaga P et al. | β | 2024 | β |
| Comorbid psychiatric disease significantly mediates increased rates of alcohol use disorder among patients with inflammatory and pigmentary skin disorders: a case-control study in the All of Us Research Program. | Kamal K et al. | β | 2024 | β |
| Cx43 hemichannels and panx1 channels contribute to ethanol-induced astrocyte dysfunction and damage. | GΓ³mez GI et al. | β | 2024 | β |
| Disulfiram impairs USP21-mediated MOF-K257 deubiquitination to inhibit esophageal squamous cell carcinoma progression. | Yang L et al. | β | 2024 | β |
| Emerging pharmacological targets for alcohol use disorder. | Brockway DF et al. | β | 2024 | β |
| Emerging targets for therapy in ALD: Lessons from NASH. | Singal AK et al. | β | 2024 | β |
| EndpointsΒ for Pharmacotherapy Trials for AlcoholΒ Use Disorder. | Belnap MA et al. | β | 2024 | β |
| Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: An umbrella review. | Wallach JD et al. | β | 2024 | β |
| Exercising healthy behaviors: A latent class analysis of positive coping during the COVID-19 pandemic and associations with alcohol-related and mental health outcomes. | McCabe EM et al. | β | 2024 | β |
| Greater inhibition of female rat binge alcohol intake by adrenergic receptor blockers using a novel Two-Shot rat binge drinking model. | De Oliveira Sergio T et al. | β | 2024 | β |
| Gut Hormones: Possible Mediators of Addictive Disorders? | Nestor LJ et al. | β | 2024 | β |
| Hazardous Drinking Interventions Delivered During Medical-Surgical Care: Patient and Provider Views. | Timko C et al. | β | 2024 | β |
| Human genetics and epigenetics of alcohol use disorder. | Zhou H et al. | β | 2024 | β |
| Implementation of an Evidence-Based Treatment Protocol and Order Set for Alcohol Withdrawal Syndrome. | Luzum NR et al. | β | 2024 | β |
| Improving screening, brief intervention and referral to treatment for unhealthy alcohol use in diverse, low-resourced primary care clinics. | Davis MM et al. | β | 2024 | β |
| Ketogenic diet reduces a neurobiological craving signature in inpatients with alcohol use disorder. | Wiers CE et al. | β | 2024 | β |
| Ligne directrice canadienne pour la prise en charge clinique de la consommation dβalcool Γ risque Γ©levΓ© et du trouble dβutilisation de lβalcool. | Wood E et al. | β | 2024 | β |
| Mapping Dialectical Behavior Therapy Skills to Clinical Domains Implicated in Contemporary Addiction Research: A Conceptual Synthesis and Promise for Precision Medicine. | Luk JW et al. | β | 2024 | β |
| Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder. | Kan E et al. | β | 2024 | β |
| Mesenchymal stem cells as a promising therapy for alcohol use disorder. | Gallardo J et al. | β | 2024 | β |
| MetALD: Does it require a different therapeutic option? | Marek GW et al. | β | 2024 | β |
| Need to rethink tDCS protocols for the treatment of alcohol use disorder: Insights from a randomized sham-controlled clinical trial among detoxified inpatients. | Dayal P et al. | β | 2024 | β |
| Novel intervention for alcohol-associated liver disease. | Gao FQ et al. | β | 2024 | β |
| Optogenetic inhibition of light-captured alcohol-taking striatal engrams facilitates extinction and suppresses reinstatement. | Vierkant V et al. | β | 2024 | β |
| Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder. | Anversa RG et al. | β | 2024 | β |
| Patient Perspectives on Pharmacotherapy of Alcohol Dependence. | Wellensiek J et al. | β | 2024 | β |
| Patients with early-stage alcohol-associated liver disease are at increased risk of hospital readmission and death. | Aryan M et al. | β | 2024 | β |
| Practice Facilitation to Address Unhealthy Alcohol Use in Primary Care: A Cluster Randomized Clinical Trial. | Huffstetler AN et al. | β | 2024 | β |
| Prevalence and Correlates of Heavy Alcohol use among People Living with HIV who use Unregulated Drugs in Vancouver, Canada. | Hui J et al. | β | 2024 | β |
| Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy. | Minozzi S et al. | β | 2024 | β |
| Repurposing drugs for treatment of alcohol use disorder. | Aubin HJ | β | 2024 | β |
| Risk of diabetes and hypertension in a population with alcohol use disorders. | Tseng PY et al. | β | 2024 | β |
| Telehealth and delivery of alcohol use disorder treatment in the Veterans Health Administration. | Perumalswami PV et al. | β | 2024 | β |
| The genetic landscape of substance use disorders. | Gerring ZF et al. | β | 2024 | β |
| The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropionβ+βvarenicline in rats. | Olsson Y et al. | β | 2024 | β |
| The impact of alcohol on affiliative verbal behavior: AΒ systematic review and meta-analysis. | Goodwin ME et al. | β | 2024 | β |
| The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. | Imperio CG et al. | β | 2024 | β |
| The prevalence of alcohol use disorders using alcohol use disorders identification test (AUDIT) in the Indian setting: - a systematic review and meta-analysis. | Joseph J et al. | β | 2024 | β |
| The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study. | Yang K et al. | β | 2024 | β |
| The Roles of Endogenous D2R Dopamine and ΞΌ-opioid Receptors of the Brain in Alcohol use Disorder. | Khikhmetova K et al. | β | 2024 | β |
| Translation Effectiveness of Offset Heart Rate Biofeedback as a Mindless Intervention for Alcohol Craving Among Risky Drinkers: Controlled Experiment. | Zhao Y et al. | β | 2024 | β |
| Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies. | Tareen K et al. | β | 2024 | β |
| Understanding Barriers and Assessing Education Intervention on Prescribing Naltrexone for Alcohol Use Disorder. | Noverati N et al. | β | 2024 | β |
| Understanding Nurse Perceptions of Caring for Patients With Alcohol Use Disorder: A Cross-Sectional Study. | Hyde A et al. | β | 2024 | β |
| [Acceptance and use of web-based interventions for alcohol abstinence]. | StΓΌben N et al. | β | 2023 | β |
| A cohort study examining changes in treatment patterns for alcohol use disorder among commercially insured adults in the United States during the COVID-19 pandemic. | Busch AB et al. | β | 2023 | β |
| Alcohol Abuse as a Silent Risk Factor for Purpura Fulminans and the Importance of Pneumococcal Vaccination. | Perry JC et al. | β | 2023 | β |
| Alcohol relapse prevention health care after alcohol withdrawal in New South Wales prisons, Australia: A patient file review. | Liang Y et al. | β | 2023 | β |
| Alcohol, the gut microbiome, and liver disease. | Jew MH et al. | β | 2023 | β |
| Animal models of compulsion alcohol drinking: Why we love quinine-resistant intake and what we learned from it. | De Oliveira Sergio T et al. | β | 2023 | β |
| A non-randomized pilot study protocol of a novel social support intervention for individuals in early recovery from hazardous alcohol use. | McCurdy LY et al. | β | 2023 | β |
| Association between clinical measures of unhealthy alcohol use and subsequent year hospital admissions in a primary care population. | Jack HE et al. | β | 2023 | β |
| Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. | Wood E et al. | β | 2023 | β |
| Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. | Wang L et al. | β | 2023 | β |
| Caring for a "Blue" Population: Addressing Priorities of the Officer Safety and Wellness Group in Nurse Practitioner Practice. | Kverno KS et al. | β | 2023 | β |
| Current Status of Korean Alcohol Drinking in Accordance with the Korean Alcohol Guidelines for Moderate Drinking Based on Facial Flushing. | Lee S et al. | β | 2023 | β |
| Cyclic Nucleotide Phosphodiesterases in Alcohol Use Disorders: Involving Gut Microbiota. | Hou X et al. | β | 2023 | β |
| Developing and Implementing a Web-Based Relapse Prevention Psychotherapy Program for Patients With Alcohol Use Disorder: Protocol for a Randomized Controlled Trial. | Eadie J et al. | β | 2023 | β |
| Diagnostic Criteria for Identifying Individuals at High Risk of Progression From Mild or Moderate to Severe Alcohol Use Disorder. | Miller AP et al. | β | 2023 | β |
| Disulfiram protects against abdominal aortic aneurysm by ameliorating vascular smooth muscle cells pyroptosis. | Liao F et al. | β | 2023 | β |
| Dysregulated Emotion and Trying Substances in Childhood: Insights from a Large Nationally Representative Cohort Study. | Klein RJ et al. | β | 2023 | β |
| Editorial: Genome-wide molecular mechanisms of substance use disorders. | Blokhin IO et al. | β | 2023 | β |
| Effect of a multidisciplinary approach on hospital visit continuation in the treatment of patients with alcohol dependence. | Kurata T et al. | β | 2023 | β |
| Effect of typical alcohol use and expectancies on the social manipulation of drinking behavior in a virtual bar pilot study. | Schneider Ii VJ et al. | β | 2023 | β |
| Effects of 10 add-on HF-rTMS treatment sessions on alcohol use and craving among detoxified inpatients with alcohol use disorder: a randomized sham-controlled clinical trial. | Hoven M et al. | β | 2023 | β |
| Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans. | Naps MS et al. | β | 2023 | β |
| Electrophysiological Markers of Aberrant Cue-Specific Exploration in Hazardous Drinkers. | Campbell EM et al. | β | 2023 | β |
| Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine. | Strayer RJ et al. | β | 2023 | β |
| Epidemiology and Disease Burden of Alcohol Associated Liver Disease. | Aslam A et al. | β | 2023 | β |
| Evaluation of a Primary E-Health Intervention for People with Alcohol Use Disorder: Clinical Characteristics of Users and Efficacy. | StΓΌben N et al. | β | 2023 | β |
| Free-access intravenous alcohol self-administration in social drinkers and individuals with alcohol use disorder: Evaluation of relationships with phosphatidylethanol and self-reported alcohol consumption. | Olsson Y et al. | β | 2023 | β |
| Functional roles, regulatory mechanisms and theranostics applications of ncRNAs in alcohol use disorder. | Wang JQ et al. | β | 2023 | β |
| GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential. | Dharavath RN et al. | β | 2023 | β |
| Guidelines for integrating spirituality into the prevention and treatment of alcohol and other substance use disorders. | Rezende-Pinto A et al. | β | 2023 | β |
| High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. | Schmalz F et al. | β | 2023 | β |
| HIV Prevention and Care Among Black Cisgender Sexual Minority Men and Transgender Women: Protocol for an HIV Status-Neutral Cohort Study Using an Observational-Implementation Hybrid Approach. | Knox JR et al. | β | 2023 | β |
| Hospitalization Associated With Comorbid Psychiatric and Substance Use Disorders Among Adults With COVID-19 Treated in US Emergency Departments From April 2020 to August 2021. | Schieber LZ et al. | β | 2023 | β |
| Integrating Alcohol-Related Prevention and Treatment Into Primary Care: A Cluster Randomized Implementation Trial. | Lee AK et al. | β | 2023 | β |
| Interprofessional education as a potential foundation for future team-based prevention of alcohol use disorder. | Edwards S et al. | β | 2023 | β |
| Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. | Kelson M et al. | β | 2023 | β |
| Liver transplantation for alcohol-associated hepatitis. | Durkin C et al. | β | 2023 | β |
| Medications for Alcohol Use Disorder and Retention in Care in Medicaid-Enrolled Youth, 2014-2019. | Earlywine JJ et al. | β | 2023 | β |
| Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. | StokΕosa I et al. | β | 2023 | β |
| Medications for treating alcohol use disorder: A narrative review. | Kranzler HR et al. | β | 2023 | β |
| Mesolimbic dopamine release precedes actively sought aversive stimuli in mice. | Yawata Y et al. | β | 2023 | β |
| Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders. | Dellazizzo L et al. | β | 2023 | β |
| N-acetylcysteine improves impulse control and attenuates relapse-like alcohol intake in long-term drinking rats. | Fredriksson I et al. | β | 2023 | β |
| Neuroanatomical predictors of problematic alcohol consumption in adolescents: a systematic review of longitudinal studies. | Honarvar F et al. | β | 2023 | β |
| Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder. | Vatsalya V et al. | β | 2023 | β |
| Post-acute Withdrawal Syndrome. | Grover C et al. | β | 2023 | β |
| Prescribing Medications for Alcohol Use Disorder: A Qualitative Study of Primary Care Physician Decision Making. | Bhardwaj A et al. | β | 2023 | β |
| Prevalence and incidence of alcohol dependence: cross-sectional primary care analysis in Liverpool, UK. | Montgomery C et al. | β | 2023 | β |
| SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments. | Wang X et al. | β | 2023 | β |
| Screening for alcohol use disorder and monitoring for alcohol use in the liver clinic. | Kulkarni AV et al. | β | 2023 | β |
| Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. | Quddos F et al. | β | 2023 | β |
| Sexually dimorphic role of circadian clock genes in alcohol drinking behavior. | de Zavalia N et al. | β | 2023 | β |
| Substance use and pre-hospital crash injury severity among U.S. older adults: A five-year national cross-sectional study. | Adeyemi O et al. | β | 2023 | β |
| The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. | Margolis EB et al. | β | 2023 | β |
| The preliminary efficacy of virtual agent-assisted intelligent rehabilitation treatment (Echo app v2.0) in patients with alcohol use disorders: Study protocol for a randomized controlled trial. | Li S et al. | β | 2023 | β |
| Therapeutics for Substance-Using Women: The Need to Elucidate Sex-Specific Targets for Better-Tailored Treatments. | Fox HC et al. | β | 2023 | β |
| Therapeutic targets in alcohol-associated liver disease: progress and challenges. | Adekunle AD et al. | β | 2023 | β |
| The role of beta- and alpha-adrenergic receptors on alcohol drinking. | De Oliveira Sergio T et al. | β | 2023 | β |
| The role of nicotinic receptors in alcohol consumption. | Kamens HM et al. | β | 2023 | β |
| Time to Treat Alcohol Use Disorder in the Emergency Department. | Hawk KF et al. | β | 2023 | β |
| Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy. | Gully BJ et al. | β | 2023 | β |
| Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review. | Edinoff AN et al. | β | 2023 | β |
| Treatment retention and reductions in blood alcohol concentration (BAC) during the first 90 days of a telehealth program for alcohol use disorder. | Hallgren KA et al. | β | 2023 | β |
| Untreated substance use disorder affects glycemic control: Results in patients with type 2 diabetes served within a network of community-based healthcare centers in Florida. | Horigian VE et al. | β | 2023 | β |
| Using lickometry to infer differential contributions of salience network regions during compulsion-like alcohol drinking. | Starski PA et al. | β | 2023 | β |
| Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. | Spreer M et al. | β | 2023 | β |
| Activation of dopamine D2 receptors in the medial shell region of the nucleus accumbens increases Per1 expression to enhance alcohol consumption. | Sharma R et al. | β | 2022 | β |
| Aging successfully, but still vulnerable: Late life experiences of older adults who have recovered from alcohol use disorder. | Kermel-Schiffman I et al. | β | 2022 | β |
| Alcohol-Associated Tissue Injury: Current Views on Pathophysiological Mechanisms. | Simon L et al. | β | 2022 | β |
| Alcohol brief intervention, specialty treatment and drinking outcomes at 12 months: Results from a systematic alcohol screening and brief intervention initiative in adult primary care. | Chi FW et al. | β | 2022 | β |
| Alcohol Consumption and Cardiovascular Health. | Krittanawong C et al. | β | 2022 | β |
| Alcohol Use. | Donroe JH et al. | β | 2022 | β |
| Alcohol Use Disorder in Older Adults. | Fenollal-Maldonado G et al. | β | 2022 | β |
| Alcohol Use Disorder: Neurobiology and Therapeutics. | Yang W et al. | β | 2022 | β |
| Anxiety, depression, and substance experimentation in childhood. | Klein RJ et al. | β | 2022 | β |
| A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder. | Seneviratne C et al. | β | 2022 | β |
| Association between abnormal plasma metabolism and brain atrophy in alcohol-dependent patients. | Zhang Z et al. | β | 2022 | β |
| Behavioral economic analysis of topiramate pharmacotherapy for alcohol: a placebo-controlled investigation of effects on alcohol reinforcing value and delayed reward discounting. | Goodyear K et al. | β | 2022 | β |
| Brain Correlates of the Alcohol Use Disorder Pharmacotherapy Response: A Systematic Review of Neuroimaging Studies. | Florence L et al. | β | 2022 | β |
| Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD. | Hoyt JE et al. | β | 2022 | β |
| Chronic Alcohol Consumption and its Impact on Bone and Metabolic Health - A Narrative Review. | Johnson JT et al. | β | 2022 | β |
| Clinical management of the alcohol withdrawal syndrome. | Day E et al. | β | 2022 | β |
| Clinicians' perspectives and perceived barriers to caring for patients with alcohol use disorder and cirrhosis. | Johnson E et al. | β | 2022 | β |
| College students' receptiveness to intervention approaches for alcohol and cannabis use. | Helle AC et al. | β | 2022 | β |
| COVID-19 pandemic-related changes in utilization of telehealth and treatment overall for alcohol use problems. | Palzes VA et al. | β | 2022 | β |
| Curative effect observation among patients with alcohol dependence in rehabilitation period by grouping motivational interviewing. | Xu Y et al. | β | 2022 | β |
| Disulfiram ameliorates ischemia/reperfusion-induced acute kidney injury by suppressing the caspase-11-GSDMD pathway. | Cai Q et al. | β | 2022 | β |
| Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. | Murphy CE et al. | β | 2022 | β |
| Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice. | ElsilΓ€ LV et al. | β | 2022 | β |
| Electroencephalographic neurofeedback as a tool for reducing harm and risk associated with alcohol use disorder: A critical review. | Lima KHM et al. | β | 2022 | β |
| Elevated Oxytocin Receptor Blood Concentrations Predict Higher Risk for, More, and Earlier 24-Month Hospital Readmissions after In-Patient Detoxification in Males with Alcohol Use Disorder. | MΓΌhle C et al. | β | 2022 | β |
| Epigenetic modification in alcohol-related liver diseases. | Ajoolabady A et al. | β | 2022 | β |
| Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). | Antwerpes S et al. | β | 2022 | β |
| Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. | Klausen MK et al. | β | 2022 | β |
| Gender Differences in the Psychosocial Determinants Underlying the Onset and Maintenance of Alcohol Use Disorder. | Maxwell AM et al. | β | 2022 | β |
| Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study. | Tsermpini EE et al. | β | 2022 | β |
| Hazardous drinking and alcohol use disorders. | MacKillop J et al. | β | 2022 | β |
| High Polygenic Risk Scores Are Associated With Early Age of Onset of Alcohol Use Disorder in Adolescents and Young Adults at Risk. | Nurnberger JI et al. | β | 2022 | β |
| Hospital Readmission in Alcohol Use Disorder Patients: The Role of Anti-Craving Medications and Discharge Disposition. | Calabrese J et al. | β | 2022 | β |
| Improving screening, treatment, and intervention for unhealthy alcohol use in primary care through clinic, practice-based research network, and health plan partnerships: Protocol of the ANTECEDENT study. | Singh AN et al. | β | 2022 | β |
| Impulsive trait mediates the relationship between white matter integrity of prefrontal-striatal circuits and the severity of dependence in alcoholism. | Wu F et al. | β | 2022 | β |
| Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. | Vannier AGL et al. | β | 2022 | β |
| Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis. | Toda E et al. | β | 2022 | β |
| Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis. | Wilson JD et al. | β | 2022 | β |
| Integrating Oral, Physical, and Mental Health Via Public Health Literacy. | Schillinger D et al. | β | 2022 | β |
| Liver Biopsy in Patients With Alcohol-Associated Liver Disease With Acute-on-Chronic Liver Failure. | Jophlin L et al. | β | 2022 | β |
| Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. | Louvet A et al. | β | 2022 | β |
| Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease. | Murthy P et al. | β | 2022 | β |
| Markers of Neuroinflammation in the Serum of Prepubertal Children with Fetal Alcohol Spectrum Disorders. | Fiore M et al. | β | 2022 | β |
| MCPIP1 alleviated alcohol-induced immune dysfunction via the MAPK/ERK signaling pathway. | Shen Y et al. | β | 2022 | β |
| Medical Detoxification for Nonopioid Substances Is Associated With Lower Likelihood of Subsequent Linkage to Substance Use Disorder Treatment. | MacKinnon L et al. | β | 2022 | β |
| Medications and Patient Factors Associated With Increased Readmission for Alcohol-Related Diagnoses. | Osborne JC et al. | β | 2022 | β |
| Neurobiological mechanisms of control in alcohol use disorder - Moving towards mechanism-based non-invasive brain stimulation treatments. | Ghin F et al. | β | 2022 | β |
| Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. | Burnette EM et al. | β | 2022 | β |
| On the Role of Stimulus-Response Context in Inhibitory Control in Alcohol Use Disorder. | Ghin F et al. | β | 2022 | β |
| Outcomes of Hospitalized Acute Alcoholic Hepatitis (AH) in Patients With Bipolar 1 Disorder (B1D). | Kaye AJ et al. | β | 2022 | β |
| Peptidylglycine Ξ±-amidating monooxygenase as a therapeutic target or biomarker for human diseases. | Merkler DJ et al. | β | 2022 | β |
| Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York. | AlegrΓa M et al. | β | 2022 | β |
| Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis. | Bahji A et al. | β | 2022 | β |
| Pituitary adenylate cyclase-activating polypeptide type 1 receptor within the nucleus accumbens core mediates excessive alcohol drinking in alcohol-preferring rats. | Minnig MA et al. | β | 2022 | β |
| Predicting severe alcohol use disorders in primary care using number of heavy drinking days. | Metz VE et al. | β | 2022 | β |
| Prevalence and Treatment for Alcohol Use Disorders Based on Kentucky Medicaid 2012-2019 Datasets. | Hu H et al. | β | 2022 | β |
| Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA. | Singal AK et al. | β | 2022 | β |
| Reciprocal associations between implicit attitudes and drinking in emerging adulthood. | Paige KJ et al. | β | 2022 | β |
| Recovery Ecosystems: A Whole Health Approach to Substance Use Prevention and Treatment. | Mumba MN et al. | β | 2022 | β |
| Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry. | Borrego MB et al. | β | 2022 | β |
| Retinoic acid inhibitors mitigate vision loss in a mouse model of retinal degeneration. | Telias M et al. | β | 2022 | β |
| Rewarding effect of ethanol-induced conditioned place preference in mice: Effect of the monoterpenoid linalool. | YunusoΔlu O | β | 2022 | β |
| RNA biomarkers for alcohol use disorder. | Ferguson LB et al. | β | 2022 | β |
| Smartphone Alcohol Use Disorder Recovery Apps: Cross-sectional Survey of Behavioral Intention to Use. | Menon R et al. | β | 2022 | β |
| Structural differences in adolescent brains can predict alcohol misuse. | Rane RP et al. | β | 2022 | β |
| Substance abuse and neurotransmission. | Davis S et al. | β | 2022 | β |
| Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial. | Santos GM et al. | β | 2022 | β |
| Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder. | Lohoff FW | β | 2022 | β |
| The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review. | van Amsterdam J et al. | β | 2022 | β |
| The altered functional connectivity density related to cognitive impairment in alcoholics. | Duan R et al. | β | 2022 | β |
| The Association of P300 Components With Clinical Characteristics and Efficacy of Pharmacotherapy in Alcohol Use Disorder. | Yuan J et al. | β | 2022 | β |
| The Development and Implementation of a Hospitalist-Directed Addiction Medicine Consultation Service to Address a Treatment Gap. | Calcaterra SL et al. | β | 2022 | β |
| The effect of neuroimmune modulation on subjective response to alcohol in the natural environment. | Meredith LR et al. | β | 2022 | β |
| The Effects of Menstrual Cycle Hormones on Responses to Varenicline and Naltrexone Among Female Heavy Drinking Smokers. | Green R et al. | β | 2022 | β |
| The Impact of Alcohol-Induced Dysbiosis on Diseases and Disorders of the Central Nervous System. | Liu X et al. | β | 2022 | β |
| The oral microbiome in alcohol use disorder: a longitudinal analysis during inpatient treatment. | Barb JJ et al. | β | 2022 | β |
| The Regulation and Modification of GSDMD Signaling in Diseases. | Li Z et al. | β | 2022 | β |
| The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. | Klausen MK et al. | β | 2022 | β |
| The Social Context of Unhealthy Alcohol Use Among Emergency Department Patients: A Cross Sectional Study. | Anderson ES et al. | β | 2022 | β |
| The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review. | Sepulveda Ramos C et al. | β | 2022 | β |
| Treatment of substance use disorders among black and white adults: rates, correlates, and racial discrimination. | Bommersbach TJ et al. | β | 2022 | β |
| A cascade of care for alcohol use disorder: Using 2015-2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. | Mintz CM et al. | β | 2021 | β |
| Addiction and the kynurenine pathway: A new dancing couple? | Morales-Puerto N et al. | β | 2021 | β |
| Agreement between DSM-5 and DSM-IV measures of substance use disorders in a sample of adult substance users. | Livne O et al. | β | 2021 | β |
| Alcohol withdrawal syndrome in ICU patients: Clinical features, management, and outcome predictors. | Vigouroux A et al. | β | 2021 | β |
| Allele-specific expression and high-throughput reporter assay reveal functional genetic variants associated with alcohol use disorders. | Rao X et al. | β | 2021 | β |
| A matched-control analysis on the effects of alcohol use disorder following primary reverse shoulder arthroplasty. | Nassis E et al. | β | 2021 | β |
| An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. | Mintz CM et al. | β | 2021 | β |
| An integrated multimodal model of alcohol use disorder generated by data-driven causal discovery analysis. | Rawls E et al. | β | 2021 | β |
| An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder. | Mariani JJ et al. | β | 2021 | β |
| A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. | Silva J et al. | β | 2021 | β |
| Antisense-induced knockdown of cAMP response element-binding protein downregulates Per1 gene expression in the shell region of nucleus accumbens resulting in reduced alcohol consumption in mice. | Sharma R et al. | β | 2021 | β |
| Baclofen therapeutics, toxicity, and withdrawal: A narrative review. | Romito JW et al. | β | 2021 | β |
| Burden of alcohol use disorders in China and the regions with different income levels over the world. | Qu X et al. | β | 2021 | β |
| Chemical analysis of the human brain by imaging mass spectrometry. | Ajith A et al. | β | 2021 | β |
| Chronic binge alcohol and ovariectomy-mediated impaired insulin responsiveness in SIV-infected female rhesus macaques. | Simon L et al. | β | 2021 | β |
| Chronic intermittent ethanol and lipopolysaccharide exposure differentially alter Iba1-derived microglia morphology in the prelimbic cortex and nucleus accumbens core of male Long-Evans rats. | Siemsen BM et al. | β | 2021 | β |
| Comorbid Bipolar and Alcohol Use Disorder-A Therapeutic Challenge. | Grunze H et al. | β | 2021 | β |
| Compulsive alcohol consumption is regulated by dorsal striatum fast-spiking interneurons. | Patton MS et al. | β | 2021 | β |
| Correlates of mild, moderate, and severe Alcohol Use Disorder among adults with problem substance use: Validity implications for DSM-5. | Mannes ZL et al. | β | 2021 | β |
| Current state and future perspective of drug repurposing in malignant glioma. | Siegelin MD et al. | β | 2021 | β |
| Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review. | Singal AK et al. | β | 2021 | β |
| Diagnosis of Alcohol-Associated Hepatitis: When Is Liver Biopsy Required? | Arab JP et al. | β | 2021 | β |
| Drinking reduction during cognitive behavioral therapy for alcohol use disorder is associated with a reduction in anterior insula-bed nucleus of the stria terminalis resting-state functional connectivity. | Srivastava AB et al. | β | 2021 | β |
| Dysregulation of Nociceptin/Orphanin FQ and Dynorphin Systems in the Extended Amygdala of Alcohol Preferring Marchigian Sardinian (msP) Rats. | Caputi FF et al. | β | 2021 | β |
| Educational attainment impacts drinking behaviors and risk for alcohol dependence: results from a two-sample Mendelian randomization study with ~780,000 participants. | Rosoff DB et al. | β | 2021 | β |
| Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. | Palzes VA et al. | β | 2021 | β |
| Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial. | Wetherill RR et al. | β | 2021 | β |
| Epigenetic modification in alcohol use disorder and alcoholic cardiomyopathy: From pathophysiology to therapeutic opportunities. | Wu L et al. | β | 2021 | β |
| Gastro protecting influence of Topiramate in ethanol produced gastric ulcers in rats. | Kadasah S et al. | β | 2021 | β |
| Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes. | Anderson ES et al. | β | 2021 | β |
| Linking Ethanol-Addictive Behaviors With Brain Catecholamines: Release Pattern Matters. | Grinevich VP et al. | β | 2021 | β |
| Neurobiological correlates of cue-reactivity in alcohol-use disorders: A voxel-wise meta-analysis of fMRI studies. | Zeng J et al. | β | 2021 | β |
| New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. | Morley KC et al. | β | 2021 | β |
| [Pharmacotherapy of alcohol withdrawal: update and new developments]. | Soyka M et al. | β | 2021 | β |
| Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder. | Mariani JJ et al. | β | 2021 | β |
| Rats exposed to chronic alcohol display protracted insomnia and daytime sleepiness-like behavior during alcohol withdrawal<sup>β°</sup>. | Sharma R et al. | β | 2021 | β |
| Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125β556 patients. | Heikkinen M et al. | β | 2021 | β |
| Reduced motor cortex GABA<sub>B</sub>R function following chronic alcohol exposure. | Peng SY et al. | β | 2021 | β |
| Response to "Alcohol and COVID-19: How Do We Respond to This Growing Public Health Crisis?" | Barrett E et al. | β | 2021 | β |
| Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial. | Johns SE et al. | β | 2021 | β |
| Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies. | Munn-Chernoff MA et al. | β | 2021 | β |
| Studying Sex Differences in Rodent Models of Addictive Behavior. | Radke AK et al. | β | 2021 | β |
| Subjective Responses to Alcohol in the Development and Maintenance of Alcohol Use Disorder. | King A et al. | β | 2021 | β |
| Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. | Winters ND et al. | β | 2021 | β |
| The 5-HT<sub>2C</sub> receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment-seeking individuals. | Campbell EJ et al. | β | 2021 | β |
| The future of translational research on alcohol use disorder. | Ray LA et al. | β | 2021 | β |
| Treating alcohol use disorders in primary care - a qualitative evaluation of a new innovation: the 15-method. | Wallhed Finn S et al. | β | 2021 | β |
| Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States. | Davy-Mendez T et al. | β | 2021 | β |
| Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities. | Qeadan F et al. | β | 2021 | β |
| Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement. | Venegas A et al. | β | 2021 | β |
| Use of Medications for Alcohol Use Disorder in the US: Results From the 2019 National Survey on Drug Use and Health. | Han B et al. | β | 2021 | β |
| Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012. | Agabio R et al. | β | 2021 | β |
| Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study. | Konrad G et al. | β | 2021 | β |
| [A double blind placebo controlled randomized clinical trial of the efficacy and safety of pregabalin in induction of remission in patients with alcohol dependence]. | Krupitsky EM et al. | β | 2020 | β |
| Alcohol and Pain: A Translational Review of Preclinical and Clinical Findings to Inform Future Treatment Strategies. | Edwards S et al. | β | 2020 | β |
| Alcohol consumption alters Gdnf promoter methylation and expression in rats. | Maier HB et al. | β | 2020 | β |
| Alcohol intake reduction for controlling hypertension. | Acin MT et al. | β | 2020 | β |
| Allosteric modulation of muscarinic receptors in alcohol and substance use disorders. | Walker LC et al. | β | 2020 | β |
| A novel human laboratory model for screening medications for alcohol use disorder. | Ho D et al. | β | 2020 | β |
| Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. | Abraham AJ et al. | β | 2020 | β |
| Brain Structure and Function in Recovery. | Nixon SJ et al. | β | 2020 | β |
| Case Study: Naltrexone for the Treatment of Nitrous Oxide Use. | Ickowicz S et al. | β | 2020 | β |
| Central amygdala mineralocorticoid receptors modulate alcohol self-administration. | Makhijani VH et al. | β | 2020 | β |
| Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. | Ray LA et al. | β | 2020 | β |
| Considering Drug-Associated Contexts in Substance Use Disorders and Treatment Development. | LeCocq MR et al. | β | 2020 | β |
| Current Management of Alcohol-Associated Liver Disease. | Siddiqi FA et al. | β | 2020 | β |
| Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. | Haass-Koffler CL et al. | β | 2020 | β |
| Documented brief intervention associated with reduced linkage to specialty addictions treatment in a national sample of VA patients with unhealthy alcohol use with and without alcohol use disorders. | Frost MC et al. | β | 2020 | β |
| Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats. | Chandler CM et al. | β | 2020 | β |
| Effects of Paternal Preconception Vapor Alcohol Exposure Paradigms on Behavioral Responses in Offspring. | Rathod RS et al. | β | 2020 | β |
| Essential Amino Acid Supplement Lowers Intrahepatic Lipid despite Excess Alcohol Consumption. | Coker MS et al. | β | 2020 | β |
| Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls. | Fairbanks J et al. | β | 2020 | β |
| Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions. | Fricker LD et al. | β | 2020 | β |
| Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. | Rutkofsky IH et al. | β | 2020 | β |
| Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis. | Cheng YC et al. | β | 2020 | β |
| Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. | McGinnis KA et al. | β | 2020 | β |
| Improving Care Provision to Older Adults with Dual Diagnosis: Recommendations from a Mixed-Methods Study. | Searby A et al. | β | 2020 | β |
| Intranasal Insulin: a Treatment Strategy for Addiction. | Kashyap B et al. | β | 2020 | β |
| Molecular mechanisms of psychiatric diseases. | Blokhin IO et al. | β | 2020 | β |
| Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder. | Strong CE et al. | β | 2020 | β |
| OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. | Hendershot CS et al. | β | 2020 | β |
| Orexin gene expression is downregulated in alcohol dependent rats during acute alcohol withdrawal. | Sharma R et al. | β | 2020 | β |
| Perineuronal nets in the insula regulate aversion-resistant alcohol drinking. | Chen H et al. | β | 2020 | β |
| Pharmacotherapeutic management of co-morbid alcohol and opioid use. | Hood LE et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. | Avila MA et al. | β | 2020 | β |
| Receptor Tyrosine Kinases as Therapeutic Targets for Alcohol Use Disorder. | Hamada K et al. | β | 2020 | β |
| Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward. | Segher K et al. | β | 2020 | β |
| Role of Hippocampal Neurogenesis in Alcohol Withdrawal Seizures. | Basu S et al. | β | 2020 | β |
| Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms. | Sayre M et al. | β | 2020 | β |
| Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system. | Valenza M et al. | β | 2020 | β |
| Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder. | Ehrie J et al. | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| Targeting zinc metalloenzymes in coronavirus disease 2019. | Doboszewska U et al. | β | 2020 | β |
| Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. | Matheson J et al. | β | 2020 | β |
| The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder. | Caputo F et al. | β | 2020 | β |
| The role of impulsivity as predisposing behavioural trait in different aspects of alcohol self-administration in rats. | Pattij T et al. | β | 2020 | β |
| Treatment of Depression With Alcohol and Substance Dependence: A Systematic Review. | Alsheikh AM et al. | β | 2020 | β |
| Why Timing Matters in Alcohol Use Disorder Recovery. | Sullivan EV | β | 2020 | β |
| Adding an orange to the banana bag: vitamin C deficiency is common in alcohol use disorders. | Marik PE et al. | β | 2019 | β |
| Advances in the science and treatment of alcohol use disorder. | Witkiewitz K et al. | β | 2019 | β |
| Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA). | Pezzilli R et al. | β | 2019 | β |
| Alcohol use disorders. | Carvalho AF et al. | β | 2019 | β |
| Allele-Specific Expression and High-Throughput Reporter Assay Reveal Functional Variants in Human Brains with Alcohol Use Disorders | Rao X et al. | β | 2019 | β |
| Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. | Rentsch CT et al. | β | 2019 | β |
| Bifunctional opioid receptor ligands as novel analgesics. | Cunningham CW et al. | β | 2019 | β |
| Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. | Turna J et al. | β | 2019 | β |
| Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. | Burchi E et al. | β | 2019 | β |
| Epidemiology of Alcohol Use and Alcoholic Liver Disease. | Mellinger JL | β | 2019 | β |
| HIV and alcohol use disorder: we cannot ignore the elephant in the room. | Agabio R et al. | β | 2019 | β |
| Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders. | Melbourne JK et al. | β | 2019 | β |
| Mood Disorders and Severity of Addiction in Alcohol-Dependent Patients Could Be Mediated by Sex Differences. | Palma-Γlvarez RF et al. | β | 2019 | β |
| Novel Adenosine Analog, <i>N</i>6-(4-Hydroxybenzyl)-Adenosine, Dampens Alcohol Drinking and Seeking Behaviors. | Hong SI et al. | β | 2019 | β |
| Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. | RΓΆsner S et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Predictors of Alcohol Use Disorders Among Young Adults: A Systematic Review of Longitudinal Studies. | Meque I et al. | β | 2019 | β |
| Predisposition to Alcohol Drinking and Alcohol Consumption Alter Expression of Calcitonin Gene-Related Peptide, Neuropeptide Y, and Microglia in Bed Nucleus of Stria Terminalis in a Subnucleus-Specific Manner. | Rossetti I et al. | β | 2019 | β |
| Prevention, screening, and treatment for heavy drinking and alcohol use disorder. | Knox J et al. | β | 2019 | β |
| Psychiatric comorbidities in alcohol use disorder. | Castillo-Carniglia A et al. | β | 2019 | β |
| Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo. | Cook RL et al. | β | 2019 | β |
| Selecting an appropriate alcohol pharmacotherapy: review of recent findings. | CastrΓ©n S et al. | β | 2019 | β |
| Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis. | Panin F et al. | β | 2019 | β |
| Understanding Addiction Using Animal Models. | Kuhn BN et al. | β | 2019 | β |